Introduction Hangzhou Tigermed Consulting Co., Ltd. specializes in offering comprehensive clinical research services for the development of pharmaceutical and health-related products both domestically and internationally. The range of services provided by the company encompasses technical support throughout phases I to IV of clinical trials, assistance with the registration and declaration of clinical trials, on-site services, as well as proficient data management and analysis. Established on December 15, 2004, the company is based in Hangzhou, China, and has emerged as a key player in the field of clinical research and development. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Polymer | 2 |
Target |
Mechanism ETA antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date19 Mar 2024 |
Target |
Mechanism C5AR1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Japan |
First Approval Date27 Sep 2021 |
Target- |
Mechanism Fe modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date26 Jun 2007 |
Start Date01 Sep 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Avacopan ( C5AR1 ) | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis More | Approved |
Iron sucrose ( Phosphates ) | Chronic Kidney Diseases More | Approved |
Ferric Carboxymaltose | Anemia, Iron-Deficiency More | Approved |
Aprocitentan ( ETA x ETB ) | Resistant hypertension More | Phase 3 |
OQL-011 ( sGC ) | Skin Diseases More | Phase 2 |